SK500172015A3 - - Google Patents

Info

Publication number
SK500172015A3
SK500172015A3 SK500172015A SK500172015A SK500172015A3 SK 500172015 A3 SK500172015 A3 SK 500172015A3 SK 500172015 A SK500172015 A SK 500172015A SK 500172015 A SK500172015 A SK 500172015A SK 500172015 A3 SK500172015 A3 SK 500172015A3
Authority
SK
Slovakia
Prior art keywords
baff
antibodies
receptor
methods
chimeric molecules
Prior art date
Application number
SK500172015A
Other languages
English (en)
Slovak (sk)
Other versions
SK288603B6 (sk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27386828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK500172015(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of SK500172015A3 publication Critical patent/SK500172015A3/sk
Publication of SK288603B6 publication Critical patent/SK288603B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
SK50017-2015A 1999-08-17 2000-08-16 Polypeptid a protilátka viažuca sa na polypeptid SK288603B6 (sk)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14937899P 1999-08-17 1999-08-17
US18168400P 2000-02-11 2000-02-11
US18353600P 2000-02-18 2000-02-18
PCT/US2000/022507 WO2001012812A2 (en) 1999-08-17 2000-08-16 Baff receptor (bcma), an immunoregulatory agent

Publications (2)

Publication Number Publication Date
SK500172015A3 true SK500172015A3 (enExample) 2002-07-02
SK288603B6 SK288603B6 (sk) 2018-10-01

Family

ID=27386828

Family Applications (2)

Application Number Title Priority Date Filing Date
SK50017-2015A SK288603B6 (sk) 1999-08-17 2000-08-16 Polypeptid a protilátka viažuca sa na polypeptid
SK229-2002A SK288287B6 (sk) 1999-08-17 2000-08-16 Protilátka proti sekvencii SEQ ID No: 1 alebo polypeptid s jej obsahom a ich použitie

Family Applications After (1)

Application Number Title Priority Date Filing Date
SK229-2002A SK288287B6 (sk) 1999-08-17 2000-08-16 Protilátka proti sekvencii SEQ ID No: 1 alebo polypeptid s jej obsahom a ich použitie

Country Status (29)

Country Link
US (7) US7691804B2 (enExample)
EP (3) EP1210425B2 (enExample)
JP (4) JP4787439B2 (enExample)
KR (2) KR100897082B1 (enExample)
CN (1) CN100447244C (enExample)
AT (1) ATE360693T1 (enExample)
AU (1) AU780240B2 (enExample)
BG (1) BG106519A (enExample)
BR (2) BR0013391A (enExample)
CA (1) CA2383154C (enExample)
CZ (1) CZ300364B6 (enExample)
DE (1) DE60034579T3 (enExample)
DK (1) DK1210425T4 (enExample)
EA (1) EA004635B1 (enExample)
EE (1) EE05673B1 (enExample)
GE (1) GEP20053685B (enExample)
HK (1) HK1043608B (enExample)
HU (3) HU230583B1 (enExample)
IL (3) IL148089A0 (enExample)
IS (1) IS2955B (enExample)
MX (1) MXPA02001665A (enExample)
NO (2) NO331410B1 (enExample)
NZ (1) NZ517782A (enExample)
PL (2) PL211786B1 (enExample)
RS (1) RS51157B (enExample)
SK (2) SK288603B6 (enExample)
TR (1) TR200201063T2 (enExample)
UA (1) UA75049C2 (enExample)
WO (1) WO2001012812A2 (enExample)

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) * 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US20050100548A1 (en) * 2001-07-24 2005-05-12 Biogen Idec Ma Inc. BAFF, inhibitors thereof and their use in the modulation of B-cell response
US6475987B1 (en) 1999-05-06 2002-11-05 National Jewish Medical And Research Center Tall-1 receptor homologues
EP1210425B2 (en) 1999-08-17 2015-06-17 Biogen MA Inc. Baff receptor (bcma), an immunoregulatory agent
UA74798C2 (uk) * 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
PT1255558E (pt) * 2000-02-16 2006-11-30 Genentech Inc Anticorpos anti-april e células hibridoma
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US7371388B1 (en) 2000-05-04 2008-05-13 Human Genome Sciences, Inc. Treatment of Sjogren's syndrome by administration of TR18 polypeptides
CA2408617A1 (en) * 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
EP2275449B1 (en) * 2000-06-16 2016-09-28 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to BLyS
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US20030091565A1 (en) 2000-08-18 2003-05-15 Beltzer James P. Binding polypeptides and methods based thereon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
DE10049010A1 (de) * 2000-10-04 2002-04-18 Boehringer Ingelheim Int Transferrin-Polykation/DNS-Komplexe für die systemische Therapie von Tumorerkrankungen mit zytotoxischen Proteinen
DK1436003T3 (da) 2001-05-24 2010-03-15 Zymogenetics Inc TACI-immunoglobulin-fusionsproteiner
KR20040019105A (ko) * 2001-08-03 2004-03-04 제넨테크, 인크. ＴＡＣＩｓ 및 ＢＲ3 폴리펩티드 및 이의 용도
US20080267965A1 (en) * 2002-02-21 2008-10-30 Kalled Susan L Use of Bcma as an Immunoregulatory Agent
AU2003256836A1 (en) * 2002-07-25 2004-02-16 Genentech, Inc. Taci antibodies and uses thereof
AU2004233164B2 (en) * 2003-03-28 2009-10-08 Biogen Ma Inc. Truncated BAFF receptors
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
EP2272868B1 (en) * 2003-06-05 2015-03-04 Genentech, Inc. Combination therapy for B cell disorders
MXPA06004301A (es) 2003-10-20 2006-06-05 Biogen Idec Inc Regimenes terapeuticos para antagonistas del factor de activacion de celulas b.
WO2005075511A1 (en) * 2004-01-29 2005-08-18 Genentech, Inc. Variants of the extracellular domain of bcma and uses thereof
AU2005305182A1 (en) * 2004-11-04 2006-05-18 Genentech, Inc. Polypeptides that bind BAFF and/or APRIL
CA2590461A1 (en) * 2004-12-23 2006-06-29 Laboratoires Serono S.A. Bcma polypeptides and uses thereof
CA2596276A1 (en) * 2005-01-28 2006-08-03 Biogen Idec Ma Inc. Use of baff to treat th2-mediated conditions
AU2006278227B2 (en) 2005-08-09 2011-10-20 Ares Trading S.A. Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
ZA200801354B (en) 2005-08-09 2009-08-26 Ares Trading Sa Methods for treating B-cell malignancies using TACI-lg fusion molecule
EA015860B1 (ru) * 2005-10-13 2011-12-30 Хьюман Дженом Сайенсиз, Инк. Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
CA2629306A1 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
EA015342B1 (ru) 2006-05-15 2011-06-30 Арес Трейдинг С.А. Способы лечения аутоиммунных заболеваний с использованием слитой молекулы taci-ig
JP5767109B2 (ja) 2008-07-17 2015-08-19 ノバルティス アーゲー 治療抗体を用いる組成物及び方法
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
WO2010093993A2 (en) * 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
HRP20161194T1 (hr) 2009-03-10 2016-11-04 Biogen Ma Inc. Anti-bcma protutijela
MX353186B (es) 2009-09-03 2018-01-05 Genentech Inc Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.
CN101781680B (zh) * 2009-10-19 2012-05-09 南通大学附属医院 测定对人baff-r基因启动子活性影响因素的方法
WO2011108008A2 (en) * 2010-03-04 2011-09-09 Transgene Biotek Ltd. Antibody for targeted induction of apoptosis, cdc and adcc mediated killing of cancer cells, tbl-cln1
CN103502472B (zh) 2011-02-28 2017-06-06 弗·哈夫曼-拉罗切有限公司 生物标记物和用于预测对b‑细胞拮抗剂的响应的方法
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
PH12013502421A1 (en) * 2011-05-27 2014-01-06 Glaxo Group Ltd Bcma (cd269/tnfrsf17) -binding proteins
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
JP2015506950A (ja) 2012-01-31 2015-03-05 ジェネンテック， インコーポレイテッド 抗ｉｇ−ｅｍ１’抗体およびそれを用いる方法
US10435474B2 (en) 2013-12-24 2019-10-08 Ossianix, Inc. Baff selective binding compounds and related methods
CN106459990B (zh) 2014-02-07 2021-06-01 麦克马斯特大学 三功能t细胞抗原偶联物及其制备方法和用途
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
WO2016014565A2 (en) 2014-07-21 2016-01-28 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
CA2961636A1 (en) 2014-09-17 2016-03-24 Boris ENGELS Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
DK3226897T3 (da) * 2014-12-05 2021-04-19 Memorial Sloan Kettering Cancer Center Antistoffer der rammer b-cellemodningsantigen og fremgangsmåder til anvendelse
SG10201900931XA (en) 2014-12-05 2019-02-27 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
JP6921001B2 (ja) 2015-04-13 2021-08-18 ファイザー・インク Ｂ細胞成熟抗原を標的にするキメラ抗原受容体
ES3012402T3 (en) 2015-04-13 2025-04-09 Pfizer Therapeutic antibodies and their uses
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
WO2017027392A1 (en) 2015-08-07 2017-02-16 Novartis Ag Treatment of cancer using chimeric cd3 receptor proteins
CN108603200B (zh) 2015-11-23 2022-08-19 诺华股份有限公司 优化的慢病毒转移载体及其用途
JP2019500394A (ja) 2015-12-30 2019-01-10 ノバルティス アーゲー 有効性が増強された免疫エフェクター細胞治療
IL311107A (en) 2016-02-17 2024-04-01 Seagen Inc BCMA antibodies and their use for the treatment of cancer and immune disorders
EP3432924A1 (en) 2016-03-23 2019-01-30 Novartis AG Cell secreted minibodies and uses thereof
EP4628094A2 (en) * 2016-06-06 2025-10-08 City of Hope Baff-r antibodies and uses thereof
EP3471773A4 (en) 2016-06-21 2020-07-08 Teneobio, Inc. ANTIBODIES BINDING CD3
UA126384C2 (uk) 2016-09-14 2022-09-28 Тенеобіо, Інк. Антитіло, яке зв'язує cd3
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
IL267485B2 (en) 2016-12-21 2024-01-01 Teneobio Inc Anti-bcma heavy chain-only antibodies and uses thereof
EP4043485A1 (en) 2017-01-26 2022-08-17 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
WO2018144535A1 (en) 2017-01-31 2018-08-09 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
US20200048359A1 (en) 2017-02-28 2020-02-13 Novartis Ag Shp inhibitor compositions and uses for chimeric antigen receptor therapy
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
MY201573A (en) 2017-05-12 2024-03-02 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
KR20250007003A (ko) 2017-06-20 2025-01-13 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
EP3652209A2 (en) 2017-07-11 2020-05-20 Compass Therapeutics LLC Agonist antibodies that bind human cd137 and uses thereof
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
WO2019071358A1 (en) 2017-10-12 2019-04-18 Mcmaster University Y182T MUTATION T CELL ANTIGEN COUPLEUR AND METHODS AND USES THEREOF
BR112020007576A2 (pt) 2017-10-18 2020-09-24 Novartis Ag composições e métodos para degradação de proteína seletiva
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
US20210179709A1 (en) 2017-10-31 2021-06-17 Novartis Ag Anti-car compositions and methods
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
BR112020008638A2 (pt) 2017-11-01 2020-10-20 Juno Therapeutics Inc receptores de antígenos quiméricos específicos para antígenos de maturação de células b (bcma)
CA3080904A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
AU2018359907A1 (en) 2017-11-06 2020-05-07 Fred Hutchinson Cancer Center Combination of a cell therapy and a gamma secretase inhibitor
US20200360431A1 (en) 2017-11-15 2020-11-19 Novartis Ag Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
US11851497B2 (en) 2017-11-20 2023-12-26 Compass Therapeutics Llc CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
TW201925782A (zh) 2017-11-30 2019-07-01 瑞士商諾華公司 靶向bcma之嵌合抗原受體及其用途
TW201930591A (zh) 2018-01-08 2019-08-01 瑞士商諾華公司 用於與嵌合抗原受體療法併用之免疫增強rna
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
CA3090249A1 (en) 2018-01-31 2019-08-08 Novartis Ag Combination therapy using a chimeric antigen receptor
WO2019160956A1 (en) 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
US20210047405A1 (en) 2018-04-27 2021-02-18 Novartis Ag Car t cell therapies with enhanced efficacy
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
JP7542441B2 (ja) 2018-05-11 2024-08-30 クリスパー セラピューティクス アクチェンゲゼルシャフト 癌を治療するための方法及び組成物
US20210213063A1 (en) 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
TWI848951B (zh) 2018-06-01 2024-07-21 瑞士商諾華公司 針對ｂｃｍａ之結合分子及其用途
WO2019237035A1 (en) 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
AU2019284911A1 (en) 2018-06-13 2020-12-17 Novartis Ag BCMA chimeric antigen receptors and uses thereof
AU2019297451A1 (en) 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
US11110123B2 (en) 2018-07-17 2021-09-07 Triumvira Immunologics Usa, Inc. T cell-antigen coupler with various construct optimizations
MD3823665T2 (ro) 2018-07-19 2024-05-31 Regeneron Pharma Receptori antigenci chimerici cu specificitate BCMA și utilizările acestora
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
ES3042082T3 (en) 2018-08-31 2025-11-18 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2020047449A2 (en) 2018-08-31 2020-03-05 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
AU2019372331A1 (en) 2018-11-01 2021-05-27 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
WO2020128972A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
ES3032659T3 (en) 2019-02-15 2025-07-23 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
ES2982474T3 (es) 2019-02-15 2024-10-16 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos
CN119661722A (zh) 2019-02-21 2025-03-21 马伦戈治疗公司 结合t细胞相关癌细胞的多功能分子及其用途
EP3927747A1 (en) 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
KR20210134339A (ko) 2019-02-25 2021-11-09 노파르티스 아게 바이러스 전달을 위한 메조다공성 실리카 입자 조성물
WO2020191316A1 (en) 2019-03-21 2020-09-24 Novartis Ag Car-t cell therapies with enhanced efficacy
CN113710707B (zh) 2019-04-05 2024-05-31 特尼奥生物股份有限公司 结合于psma的重链抗体
WO2020210678A1 (en) 2019-04-12 2020-10-15 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US20220251152A1 (en) 2019-04-24 2022-08-11 Novartis Ag Compositions and methods for selective protein degradation
US20220249558A1 (en) 2019-04-30 2022-08-11 Crispr Therapeutics Ag Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
BR112021023048A2 (pt) 2019-05-21 2022-04-19 Novartis Ag Moléculas de ligação a cd19 e usos das mesmas
CN119564852A (zh) 2019-06-14 2025-03-07 特尼奥生物股份有限公司 与cd22和cd3结合的多特异性重链抗体
US20220257796A1 (en) 2019-07-02 2022-08-18 Fred Hutchinson Cancer Research Center Recombinant ad35 vectors and related gene therapy improvements
CA3163104A1 (en) 2019-11-26 2021-06-03 Novartis Ag Chimeric antigen receptors and uses thereof
MX2022007759A (es) 2019-12-20 2022-07-19 Novartis Ag Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico.
GB2609554B (en) 2020-01-03 2025-08-20 Marengo Therapeutics Inc Anti-TCR antibody molecules and uses thereof
BR112022016633A2 (pt) 2020-02-27 2022-12-13 Novartis Ag Métodos para produzir células que expressam receptor de antígeno quimérico
US20230256017A1 (en) 2020-02-27 2023-08-17 Jennifer Brogdon Methods of making chimeric antigen receptor-expressing cells
CN115715220A (zh) 2020-04-29 2023-02-24 特尼奥生物股份有限公司 具有经修饰重链恒定区的多特异性重链抗体
US20230332104A1 (en) 2020-06-11 2023-10-19 Novartis Ag Zbtb32 inhibitors and uses thereof
MX2022015852A (es) 2020-06-23 2023-01-24 Novartis Ag Regimen de dosificacion que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
EP4188549A1 (en) 2020-08-03 2023-06-07 Novartis AG Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN116406371A (zh) * 2020-08-12 2023-07-07 斯坦福大学托管董事会 sBCMA变体及其Fc融合蛋白
US20230302155A1 (en) 2020-08-21 2023-09-28 Novartis Ag Compositions and methods for in vivo generation of car expressing cells
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
KR20240004462A (ko) 2021-04-08 2024-01-11 마렝고 테라퓨틱스, 인크. Tcr에 결합하는 다기능성 분자 및 이의 용도
CN118056008A (zh) 2021-04-27 2024-05-17 诺华股份有限公司 病毒载体生产系统
KR20240037892A (ko) 2021-06-01 2024-03-22 트리움비라 이뮤놀로직스 유에스에이, 인크. 클라우딘 18.2 t 세포-항원 커플러 및 이의 용도
US11453723B1 (en) 2021-06-25 2022-09-27 Mcmaster University BCMA T cell-antigen couplers and uses thereof
JP2024529128A (ja) 2021-08-11 2024-08-01 アクソ バイオファーマシューティカル， インコーポレイテッド ｓＢＣＭＡバリアント及びそのＦＣ融合タンパク質を使用するＩｇＡ、ＩｇＭ、及び／又はＩｇＧの産生を低減する方法
WO2023021477A1 (en) 2021-08-20 2023-02-23 Novartis Ag Methods of making chimeric antigen receptor–expressing cells
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2024089639A1 (en) 2022-10-26 2024-05-02 Novartis Ag Lentiviral formulations
WO2024197157A1 (en) 2023-03-21 2024-09-26 Biograph 55, Inc. Cd19/cd38 multispecific antibodies
WO2024243441A1 (en) 2023-05-24 2024-11-28 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
WO2025170844A1 (en) * 2024-02-05 2025-08-14 Board Of Regents, The University Of Texas System Chimeric polypeptides and methods of use

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
AU726486C (en) 1996-03-14 2004-02-05 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
BR9612752A (pt) 1996-10-25 2000-01-18 Human Genome Sciences Inc Neutrocina
WO1998027114A2 (en) 1996-12-17 1998-06-25 Schering Corporation Mammalian cell surface antigens; related reagents
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
CA2232743A1 (en) 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5
BR9808545A (pt) 1997-04-16 2000-05-23 Amgen Inc ácido nucleico isolado, vetor de expressão, célula hospedeira, processos para produzir uma proteìna de ligação da osteoprotegerina, para detectar a presença de uma proteìna de ligação à osteoprotegerina em uma amostra biológica, para avaliar a capacidade de um composto candidato de ligar-se a uma proteìna de ligação da osteoprotegerina e de um composto de teste para aumentar ou reduzir a ligação da proteìna de ligação da osteoprotegerina a odar, para regular a expressão de uma proteìna de ligação da osteoprotegerina em um animal e para prevenir ou tratar de doença óssea em um mamìfero, polipeptìdeo, protéina de ligação da osteroprotegerina purificada e isolada, ou seu fragmento, análogo ou derivado, e, anticorpo ou seu fragmento
AU743490B2 (en) 1997-06-06 2002-01-24 Regeneron Pharmaceuticals, Inc. NTN-2 member of TNF ligand family
WO1998055621A1 (en) 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
AU9376498A (en) 1997-09-05 1999-03-22 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
JP4357738B2 (ja) 1997-09-12 2009-11-04 アポテック エール エ デ− エス．アー． システインリッチなレセプターであるｔｒａｉｎ
EA005411B1 (ru) * 1997-09-12 2005-02-24 Апотек Р Энд Д Са Применение антитела против полипептида april для получения лекарственного препарата для лечения опухолей
EA200000311A1 (ru) * 1997-09-12 2000-10-30 Апотек Р Энд Д Са Новый белок иммунной системы - кау
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
AU2093499A (en) 1997-12-30 1999-07-19 Chiron Corporation Members of tnf and tnfr families
EP0947556B1 (en) * 1998-04-01 2004-11-10 Solvay Solexis, Inc. Compatible blends of polyvinylidene fluoride and aromatic polyimide
AU1467000A (en) 1998-11-04 2000-05-22 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A novel tumor necrosis factor family member, drl, and related compositions and methods
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US7833529B1 (en) * 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
DE60005135T3 (de) † 1999-01-07 2015-04-09 Zymogenetics, Inc. Lösliche rezeptoren br43x2 und verfahren zu deren therapeutischen verwendung
US20060067933A1 (en) * 1999-01-07 2006-03-30 Gross Jane A Soluble receptor BR43x2 and methods of using
CA2360062A1 (en) 1999-01-25 2000-07-27 Biogen, Inc. Baff, inhibitors thereof and their use in the modulation of b-cell response
US6475986B1 (en) 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
WO2000050633A1 (en) 1999-02-24 2000-08-31 The General Hospital Corporation Method for cloning signal transduction intermediates
WO2000058362A1 (en) 1999-03-26 2000-10-05 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon
US6475987B1 (en) 1999-05-06 2002-11-05 National Jewish Medical And Research Center Tall-1 receptor homologues
EP1210425B2 (en) 1999-08-17 2015-06-17 Biogen MA Inc. Baff receptor (bcma), an immunoregulatory agent
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
CA2399387C (en) 2000-02-11 2015-11-03 Biogen, Inc. Heterologous polypeptide of the tnf family
PT1255558E (pt) † 2000-02-16 2006-11-30 Genentech Inc Anticorpos anti-april e células hibridoma
US20040013674A1 (en) 2001-04-27 2004-01-22 Christine Ambrose Taci as an anti-tumor agent
CA2408617A1 (en) 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
EP2275449B1 (en) 2000-06-16 2016-09-28 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to BLyS
AU2001288260A1 (en) 2000-08-15 2002-03-13 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
EP1456347A4 (en) 2001-11-16 2006-08-02 Human Genome Sciences Inc ANTIBODIES BINDING TO BLYS ACCORDING TO AN IMMUNOSPECIFIC MODE
US20080267965A1 (en) 2002-02-21 2008-10-30 Kalled Susan L Use of Bcma as an Immunoregulatory Agent
US7083735B2 (en) 2003-09-03 2006-08-01 Laing David A High debris content strainer
PH12013502421A1 (en) 2011-05-27 2014-01-06 Glaxo Group Ltd Bcma (cd269/tnfrsf17) -binding proteins
FR3005792B1 (fr) 2013-05-16 2017-12-29 Parknplug Procede de gestion dynamique et previsionnel du rechargement electrique de batteries

Also Published As

Publication number Publication date
KR20090016772A (ko) 2009-02-17
JP5904985B2 (ja) 2016-04-20
NO20020789D0 (no) 2002-02-18
IL148089A0 (en) 2002-09-12
EA200200261A1 (ru) 2002-08-29
AU780240B2 (en) 2005-03-10
DK1210425T4 (en) 2015-08-10
IL230961A0 (en) 2014-03-31
NO344346B1 (no) 2019-11-11
BG106519A (bg) 2003-04-30
EE200200071A (et) 2003-04-15
BRPI0013391B1 (pt) 2018-09-11
NO20020789L (no) 2002-04-08
EP1210425B2 (en) 2015-06-17
EP1806143B1 (en) 2016-06-15
BRPI0013391B8 (pt) 2021-05-25
KR100897082B1 (ko) 2009-05-14
EP1210425A2 (en) 2002-06-05
US7083785B2 (en) 2006-08-01
US20120214687A1 (en) 2012-08-23
IL230961A (en) 2016-06-30
PL211786B1 (pl) 2012-06-29
US20180273605A1 (en) 2018-09-27
US20020165156A1 (en) 2002-11-07
NZ517782A (en) 2004-01-30
US20100040627A1 (en) 2010-02-18
NO20111232A1 (no) 2011-09-12
JP2011116790A (ja) 2011-06-16
US8828669B2 (en) 2014-09-09
PL354661A1 (en) 2004-02-09
SK2292002A3 (en) 2002-07-02
CA2383154C (en) 2013-04-30
EP2314694A2 (en) 2011-04-27
MXPA02001665A (es) 2003-07-14
DE60034579T3 (de) 2015-11-12
EP1210425B1 (en) 2007-04-25
EE05673B1 (et) 2013-08-15
GEP20053685B (en) 2005-12-12
DE60034579D1 (de) 2007-06-06
US9650430B2 (en) 2017-05-16
EP1806143A3 (en) 2007-07-18
SK288603B6 (sk) 2018-10-01
EP1806143A2 (en) 2007-07-11
RS51157B (sr) 2010-10-31
IS2955B (is) 2016-12-15
HUP0203084A2 (en) 2002-12-28
WO2001012812A2 (en) 2001-02-22
PL207501B1 (pl) 2010-12-31
JP2014037434A (ja) 2014-02-27
KR20020084842A (ko) 2002-11-11
EA004635B1 (ru) 2004-06-24
DE60034579T2 (de) 2008-01-31
TR200201063T2 (tr) 2002-10-21
HU230583B1 (hu) 2017-02-28
HU227947B1 (en) 2012-06-28
JP4787439B2 (ja) 2011-10-05
CN100447244C (zh) 2008-12-31
US20150139992A1 (en) 2015-05-21
JP2011063600A (ja) 2011-03-31
CN1379815A (zh) 2002-11-13
EP2314694A3 (en) 2013-12-11
US20020172674A1 (en) 2002-11-21
US20200095305A1 (en) 2020-03-26
JP2003507364A (ja) 2003-02-25
AU6911200A (en) 2001-03-13
HK1043608A1 (en) 2002-09-20
HU227008B1 (en) 2010-04-28
ATE360693T1 (de) 2007-05-15
IS6273A (is) 2002-02-15
UA75049C2 (uk) 2006-03-15
YU10602A (sh) 2005-06-10
HK1043608B (en) 2007-12-07
JP5379107B2 (ja) 2013-12-25
CZ300364B6 (cs) 2009-04-29
US10494416B2 (en) 2019-12-03
BR0013391A (pt) 2002-07-09
WO2001012812A3 (en) 2001-09-07
HU1000128D0 (en) 2010-05-28
NO331410B1 (no) 2011-12-19
CZ2002579A3 (cs) 2002-05-15
IL148089A (en) 2015-03-31
CA2383154A1 (en) 2001-02-22
US7691804B2 (en) 2010-04-06
DK1210425T3 (da) 2007-09-17
SK288287B6 (sk) 2015-07-01

Similar Documents

Publication Publication Date Title
SK500172015A3 (enExample)
IL148839A0 (en) April receptor (bcma) and uses thereof
IL144578A0 (en) Antibodies specific to kdr and uses thereof
AU9374198A (en) Methods for producing human antibodies in scid mice using dendritic cells
EP1053351A4 (en) NOVEL TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMIL MOLECULES AND USES THEREOF
KR960030206U (ko) 가방손잡이에 완충판의 결합구조
GB9823940D0 (en) Therapeutic antibody composition and use
GB9823934D0 (en) Therapeutic antibody composition and use
GB9823936D0 (en) Therapeutic antibody composition and use
GB9823937D0 (en) Therapeutic antibody composition and use
GB9823939D0 (en) Therapeutic antibody composition and use
GB9823931D0 (en) Therapeutic antibody composition and use
GB9823942D0 (en) Therapeutic antibody composition and use
GB9823943D0 (en) Therapeutic antibody composition and use

Legal Events

Date Code Title Description
MK4A Patent expired

Expiry date: 20200816